TCG Crossover Management as of Sept. 30, 2023
Portfolio Holdings for TCG Crossover Management
TCG Crossover Management holds 26 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Structure Therapeutics Adrs (GPCR) | 11.2 | $76M | 1.5M | 50.42 | |
| Cogent Biosciences Comm (COGT) | 8.1 | $55M | 5.6M | 9.75 | |
| Geron Corp Comm (GERN) | 7.3 | $50M | 23M | 2.12 | |
| AN2 Therapeutics Comm (ANTX) | 6.3 | $43M | 2.7M | 16.08 | |
| Savara Comm (SVRA) | 5.6 | $38M | 10M | 3.78 | |
| Taysha Gene Therapies Comm (TSHA) | 5.2 | $35M | 11M | 3.16 | |
| Kalvista Pharmaceuticals Comm (KALV) | 4.8 | $33M | 3.4M | 9.63 | |
| Inhibrx Comm (INBX) | 4.7 | $32M | 1.8M | 18.35 | |
| Aerovate Therapeutics Comm (AVTE) | 4.4 | $30M | 2.2M | 13.57 | |
| Icosavax Comm | 4.2 | $29M | 3.7M | 7.75 | |
| Compass Pathways Adrs (CMPS) | 4.2 | $29M | 3.9M | 7.40 | |
| Ventyx Biosciences Comm (VTYX) | 4.2 | $28M | 816k | 34.73 | |
| Tyra Biosciences Comm (TYRA) | 4.0 | $27M | 2.0M | 13.77 | |
| Madrigal Pharmaceuticals Comm (MDGL) | 3.9 | $26M | 180k | 146.04 | |
| Silence Therapeutics Adrs (SLN) | 3.0 | $21M | 2.1M | 9.82 | |
| Tarsus Pharmaceuticals Comm (TARS) | 3.0 | $20M | 1.1M | 17.77 | |
| Rayzebio Comm | 2.8 | $19M | 870k | 22.20 | |
| Dyne Therapeutics Comm (DYN) | 2.2 | $15M | 1.7M | 8.96 | |
| Centessa Pharmaceuticals Comm (CNTA) | 1.9 | $13M | 2.0M | 6.47 | |
| Kura Oncology Comm (KURA) | 1.9 | $13M | 1.4M | 9.12 | |
| Immunovant Comm (IMVT) | 1.9 | $13M | 335k | 38.39 | |
| Entrada Therapeutics Comm (TRDA) | 1.4 | $9.2M | 585k | 15.80 | |
| Gracell Biotechnologies Adrs | 1.3 | $8.8M | 3.0M | 2.88 | |
| Cabaletta Bio Comm (CABA) | 1.1 | $7.4M | 487k | 15.22 | |
| Merus Comm (MRUS) | 1.0 | $7.1M | 300k | 23.58 | |
| C4 Therapeutics Comm (CCCC) | 0.3 | $2.4M | 1.3M | 1.86 |
